BioengineeringbioRxiv
Glycoengineering of NK cells with glycan ligands of CD22 and selectins for B-cell lymphoma therapy
S. Hong, C. Yu, P. Wang…·P. Wu
This study modifies NK cells with CD22 and selectin glycan ligands to enhance B-cell lymphoma targeting and trafficking, achieving effective tumor suppression in a xenograft model.
DOI 10.1002/ange.202005934